Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary

Calliditas Therapeutics AB

13/08/2024 07:07

* Calliditas Therapeutics AB  CALTX.ST  reported a quarterly
adjusted loss of 88 øre​​ per share for the quarter ended in
January, higher than the same quarter last year, when the
company reported EPS of SEK-1.71.  The mean expectation of
four analysts for the quarter was for a loss of 30 cents per
share. Wall Street expected results to range from -46 øre to -20
øre per share.
    * Revenue rose 107.8% to SEK559.78 million from a year ago;
analysts expected SEK445.35 million. 
    * Calliditas Therapeutics AB's reported EPS for the quarter
was a
loss of 88 øre​.
    * The company reported a quarterly loss of SEK47.48 million.
    * Calliditas Therapeutics AB shares had risen by 0.5% this
quarter and gained 62.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 26.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Calliditas
Therapeutics AB is SEK219.00 
This summary was machine generated from LSEG data August 13 at
06:07 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.30          -0.88          Missed
 Mar. 31 2024      -1.64          -4.59          Missed
 Dec. 31 2023      -1.73          -0.34          Beat
 Sep. 30 2023      -0.28          -3.14          Missed